open access

Vol 10, No 1 (2009): Practical Diabetology
Review articles (submitted)
Published online: 2009-03-18
Get Citation

ADVANCE - how to optimize the prevention of diabetic complications. The results of pooled analysis of glucose-lowering and blood pressure arms of the ADVANCE study

Tomasz Klupa
Diabetologia Praktyczna 2009;10(1):21-28.

open access

Vol 10, No 1 (2009): Practical Diabetology
Review articles (submitted)
Published online: 2009-03-18

Abstract

The recently published results of ADVANCE trial demonstrated the separate benefits of blood pressure lowering with the fixed combination of perindopril- -indapamide and of intensive glucose control with a gliclazide MR-based regimen on a range of outcomes including vascular complications of diabetes and mortality. The study was the biggest so far prospective trial on type 2 diabetes mellitus (n = 11,140). Separate analysis of both treatment arms of ADVANCE trial was recently followed by the assassement of magnitude and independence of both, hypoglycemic and hypotensive, effects. This article summarizes main results of combined analysis. The was no interaction between blood pressure lowering and intensive glucose control for any endpoints. Individuals randomized to Perindopril/Indapamide and Diaprel MR-based intensive blood glucose lowering, were characterized by reduction of risk of all-cause mortality by 18%, cardiovascular death by 24%, development or worsening of nephropathy by 33%. These results indicate that the separate effects of Perindopril/ Indapamide and intensive glucose control with Diaprel MR were independent for all outcomes, combined use of these treatments should be of substantial benefis for T2DM patients.

Abstract

The recently published results of ADVANCE trial demonstrated the separate benefits of blood pressure lowering with the fixed combination of perindopril- -indapamide and of intensive glucose control with a gliclazide MR-based regimen on a range of outcomes including vascular complications of diabetes and mortality. The study was the biggest so far prospective trial on type 2 diabetes mellitus (n = 11,140). Separate analysis of both treatment arms of ADVANCE trial was recently followed by the assassement of magnitude and independence of both, hypoglycemic and hypotensive, effects. This article summarizes main results of combined analysis. The was no interaction between blood pressure lowering and intensive glucose control for any endpoints. Individuals randomized to Perindopril/Indapamide and Diaprel MR-based intensive blood glucose lowering, were characterized by reduction of risk of all-cause mortality by 18%, cardiovascular death by 24%, development or worsening of nephropathy by 33%. These results indicate that the separate effects of Perindopril/ Indapamide and intensive glucose control with Diaprel MR were independent for all outcomes, combined use of these treatments should be of substantial benefis for T2DM patients.
Get Citation

Keywords

ADVANCE; type 2 diabetes; hypertension; perindopril; indapamide; gliclazide; intensive control; micro- and macrovascular complications

About this article
Title

ADVANCE - how to optimize the prevention of diabetic complications. The results of pooled analysis of glucose-lowering and blood pressure arms of the ADVANCE study

Journal

Clinical Diabetology

Issue

Vol 10, No 1 (2009): Practical Diabetology

Pages

21-28

Published online

2009-03-18

Bibliographic record

Diabetologia Praktyczna 2009;10(1):21-28.

Keywords

ADVANCE
type 2 diabetes
hypertension
perindopril
indapamide
gliclazide
intensive control
micro- and macrovascular complications

Authors

Tomasz Klupa

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl